Valo Health Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
/PRNewswire/ -- Valo Health, Inc. ("Valo"), the technology company focused on transforming the drug discovery and development process using human-centric data...
Source: prnewswire.com